I nteraction of glucocorticoids with the cardiovascular system has been shown to affect cardiovascular function. In the rat, excess glucocorticoid induces a rapid increase in blood pressure. 1 Glucocorticoid-induced hypertension is also observed in humans. 2 Although it has been reported that glucocorticoids potentiate the response of vascular smooth muscle to the pressor effect of catecholamine, 3 ' 4 little is known about the molecular mechanisms by which glucocorticoids affect the blood pressure and the vascular system. A direct effect of glucocorticoid on the vascular receptors is probably involved in glucocorticoid-induced hypertension. 5 Consistent with the possibility of direct glucocorticoid effects, classical glucocorticoid receptors that bind dexamethasone have been demonstrated in vascular smooth muscle cells (VSMC) . 67 We recently demonstrated that glucocorticoid enhances prostaglandin Ei 8 and dopamine 9 receptors, which mediate cyclic adenosine monophosphate (cAMP) formation by VSMC. Because prostaglandin E, and dopamine receptors on VSMC are considered to induce vasodilation, these findings are opposite to glucocorticoid-induced hypertension.
Atrial natriuretic factor (ANF) is a hormone that induces diuresis, natriuresis, and vasodilatation. 10 One of the earliest events after binding of ANF to receptors on target cells is an increase in cyclic guanosine monophosphate (cGMP) concentration, indicating that this nucleotide might act as a mediator of such physiological effects as vasodilation. 11 -13 The membrane form of guanylate cyclase is activated after the binding of ANF to target cells. 14 - 15 More recently it was reported that a membrane form of guanylate cyclase is an ANF receptor. 16 In the present study, we examined the effect of glucocorticoids on ANF-induced cGMP formation by the membrane form of guanylate cyclase in VSMC.
Methods

Materials
Type II collagenase, dexamethasone, aldosterone, corticosterone, cortisol, progesterone, /S-estradiol, testosterone, 3-isobutyl-l-methylxanthine (IBMX), cycloheximide, and actinomycin D were purchased from Sigma Chemical Co., St. Louis, Mo. Dulbecco's modified Eagle's medium (DMEM), penicillin-streptomycin, trypsin EDTA (Versine), and fetal calf serum (FCS) were purchased from Gibco Laboratories, Grand Island, N.Y. [ 582 Hypertension Vol 16, No 5, November 1990 were purchased from Becton, Dickinson and Co., Oxnard, Calif. Anion exchange chromatography Dowex 50W-X2 was purchased from Bio Rad Laboratories, Richmond, Calif. Rat atrial natriuretic polypeptide (Rat, 1-28) was purchased from the Peptide Institute, Osaka, Japan. RU 38486 was kindly provided by Roussel Uclaf, Paris.
Cell Culture
VSMC were grown from the explants of 14-weekold normotensive Wistar rat renal arteries as previously described. 89 Animal handling was also done as previously described. 17 Cells were identified as VSMC by their morphological and growth characteristics, including growth in multilayers in a typical "hill and valley" pattern, absence of contact inhibition of growth, and the presence of myofibrils on electron microscopic examination. VSMC were grown in DMEM supplemented with 10% FCS. Cells from passage 5 through 10 were used and were subcultured after trypsinization on a weekly basis because cells become confluent in a week. Each plate was replenished twice each week with fresh medium.
Assay for Cyclic Guanosine Monophosphate Formation in Intact Cells
Receptor-mediated cGMP formation was measured by modification of the prelabeling technique of Richelson et al 18 based on the column separation method of Fujimoto et al. 19 All experiments with VSMC were conducted at least in triplicate by using six-well culture plates. Cells were preincubated with [ 3 H]guanine (2 AiCi/ml) at 37° C for 2 hours. Before incubation, cells were rinsed three times with 2 ml DMEM. In most of the experiments, cells were incubated with agonist (ANF) for 10 minutes in 2 ml DMEM in the presence of phosphodiesterase inhibitor IBMX 0.5 mM at 37° C in an atmosphere of 5% CO 2 and 95% air. Stimulation of the labeled cells was stopped by adding 1.5 ml 5% ice-cold trichloroacetic acid (TCA). In some experiments, the culture medium was replaced by DMEM with 10% FCS containing dexamethasone, aldosterone, other steroids, or the vehicle (ethanol) 48 hours before stimulation. TCA extracts were submitted to ion exchange Dowex 50W-X2 column chromatography for the isolation of [ 3 H]cGMP. Thus, each column was washed with 4.4 ml of 0.1N HC1 and 1 ml water successively before eluting cGMP with the next 1.5 ml water, which was usually collected directly into the scintillation vial. The recovery of [ 3 H]cGMP through the Dowex column was 85-95%. Radioactivity was determined by liquid scintillation counting. In one experiment, cGMP was measured by an Amersham radioimmunoassay kit. Cells were counted by an electronic cell counter (model Zf, Coulter Electronics, Hialeah, Fla.).
Statistics
Statistical analysis was performed by analysis of variance and Scheffe's modified t test. Values of /?<0.05 were considered significant. 
Results
Effect of Glucocorticoid on Atrial Natriuretic Factor-Mediated Cyclic Guanosine Monophosphate Formation by Vascular Smooth Muscle Cells
ANF stimulated the formation of cGMP by guanylate cyclase in intact VSMC from renal arteries of Wistar rats. The incubation of VSMC from renal arteries for 48 hours in the presence of dexamethasone (1 IJM) led to a suppression of ANF-mediated cGMP formation by intact cells. Dose-response curves for ANF in the dexamethasone-treated cells showed a suppression of the maximum response generally ranging from 45% to 70% below that of the untreated cells ( Figure 1 ). The basal activity of guanylate cyclase in the dexamethasone-treated cells was lower than that of control cells (dexamethasone, 80±60 versus control, 280±120; /?<0.05). The incubation of cells with dexamethasone for various periods of time before ANF stimulation of cGMP led to a detectable effect at 6 hours with a maximum effect at 24 hours. This effect was maintained for up to 72 hours, the length of the study (Figure 2 ). Time course in response to ANF shows that dexamethasone treatment for 48 hours decreases ANF-mediated cGMP formation ( Figure 3) .
Time course of cGMP formation in response to ANF for the first 2 minutes was also measured by radioimmunoassay. Dexamethasone suppression of ANF-mediated cGMP formation was also observed (Figure 4 different concentrations of aldosterone had almost no effect ( Figure 5 ).
Effect of Inhibitors of Protein Synthesis and RNA Synthesis on Dexamethasone-Mediated Suppression of Atrial Natriuretic Factor Response
Steroid hormones interact with specific cytosolic receptors that are translocated to the nuclei. This induces RNA synthesis and, consequently, the formation of new protein molecules. To determine whether glucocorticoid hormones act via a similar mechanism in VSMC, we incubated cells with either by ANF (1 /xM) for 12 minutes. Steroids having glucocorticoid activity mimicked the previously observed dexamethasone suppression of the ANF-mediated response. However, sex hormones such as testosterone had almost no effect ( Table 2) .
Effect of RU 38,486 on Dexamethasone-Induced Suppression of Cyclic Guanosine Monophosphate Formation by Atrial Natriuretic Factor
Treatment for 48 hours with RU 38,486, a specific glucocorticoid receptor antagonist, 20 reversed the dexamethasone-induced suppression of cGMP formation by ANF (Table 3) .
Discussion
It has been proposed that ANF receptors be classified as B and C receptors. 21 ANF B receptors are coupled with guanylate cyclase. 22 ANF C receptors are ANF clearance receptors, which are consid- ered to bind to ANF and clear it from the circulation. Most receptors on VSMC seem to be ANF C receptors. 23 It is considered that functions such as vasodilation are caused by guanylate cyclase through ANF B receptors.
1 '- 13 Therefore, in this study, cGMP was measured to examine the biological ANF receptor response (B receptor response). Our dose-response curve of ANF B receptor is consistent with previous reports.
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Our study has shown that the glucocorticoid, dexamethasone, decreases the ANF-mediated cGMP formation by VSMC. Dexamethasone treatment for 48 hours did not affect the cell numbers. The doseresponse curve to dexamethasone, the fact that aldosterone had almost no effect on the ANF-mediated cGMP formation, and the fact that this action is reversed by a glucocorticoid receptor antagonist suggest that this action is mediated though glucocorticoid type II receptors. The time course for glucocorticoid action, as well as the fact that inhibitors of RNA and protein synthesis block the effect, strongly support the involvement of a genomic mechanism of action and the requirement for de novo protein synthesis. This behavior is consistent with the general mode of action of steroid hormones. However, like the data on cycloheximide and actinomycin D, these findings should be interpreted with caution because the synthesis of other proteins, including the glucocorticoid receptor itself, could be inhibited at the same time. 25 There are two types of guanylate cyclase: the membrane form and the soluble form. 26 The membrane form of guanylate cyclase is an ANF receptor. 16 This study shows that ANF receptor response is modified by glucocorticoid. Plasma ANF concentration is also affected by many factors. We reported in hypertensive subjects that plasma ANF is elevated with markedly high blood pressure or left ventricular hypertrophy 27 and that sodium loading increases plasma ANF. 28 Glucocorticoid, which enhances ANF synthesis 29 as well as thyroid hormone, 30 reduces the ANF receptor response.
Glucocorticoids are known to enhance the hormonal stimulation of cAMP accumulation in many cell types 31 including astrocytoma clone D384. 32 We previously reported that glucocorticoid increases prostaglandin E, and dopamine-mediated cAMP formation in cultured VSMC. 8 ' 9 Because agonist-induced cAMP formation by VSMC is believed to induce vasodilation, these findings are contrary to glucocorticoid-induced hyperreactivity of the vascular bed in experimental animals 3 and humans. 2 In the present study, we showed that glucocorticoid decreases ANF-mediated cGMP formation. Because ANF administration is considered to cause vasodilation through activation of the membrane form of guanylate cyclase (ANF B receptor) in VSMC, these findings are consistent with a glucocorticoid-induced hyperreactivity of the vascular bed and with glucocorticoid-induced hypertension.
The cellular mechanism of glucocorticoid suppression of guanylate cyclase in VSMC remains to be elucidated. Because glucocorticoid increases agonistinduced cAMP formation in VSMC, 8 ' 9 there is a possibility that this increased cAMP formation increases phosphodiesterase activity, which then increases the breakdown of cGMP. However, suppression occurs in the presence of the phosphodiesterase inhibitor IBMX. Therefore, it is unlikely that increased adenylate cyclase activity plays some role in this suppression. Glucocorticoids may decrease the number of ANF B receptors. However, even if measurement of ANF B receptor number were possible using a specific ligand, change in ANF B receptor number would be difficult to prove since only a small portion of the ANF receptors in VSMC contain guanylate cyclase (i.e., ANF B receptors). At present, measurement of the ANF receptor number seems to be measurement of the ANF C receptor number. 23 Change in ANF receptor number may not have been helpful in the present study. Even an 80% decrease in ANF C receptor number would not affect the ANF receptor-mediated cGMP formation (ANF B receptor response). 33 Dissociation of the ANF receptor number and the ANF-mediated cGMP formation (i.e., an increased number of ANF C receptors) and blunted guanylate cyclase response has also been reported in spontaneously hypertensive rats. 34 Because the basal level of guanylate cyclase is suppressed by glucocorticoids, a possible mechanism is a direct action of glucocorticoids to suppress the catalytic unit of guanylate cyclase.
We have used a prelabeling technique to measure guanylate cyclase activity. To rule out the possibility that dexamethasone pretreatment affected the prelabeling process and to determine whether the synthesis or catabolism of cGMP was influenced by dexamethasone pretreatment, time course of cGMP formation in response to ANF for the first 2 minutes was also measured by radioimmunoassay. Dexamethasone suppression of ANF receptor response was also observed, and this suppression was observed while the time course curve was linear. Therefore, dexamethasone pretreatment, at least in part, plays a role in the decreased cGMP synthesis.
Because the peripheral vascular regulation of blood pressure is controlled mainly by arteries with only low resistance rather than by large vessels such as renal arteries, which are not considered resistance vessels, we must exercise caution in exploring our results. However, it is unlikely that the ANF-receptor gene in VSMC from renal arteries differs from the ANF receptor gene of other vessels. The advantage of the VSMC culture system used in this study is that the effect of a variety of hormones and drugs on the intact peripheral vascular cells can be individually determined.
In summary, glucocorticoid has been observed to decrease ANF-induced cGMP formation in VSMC. This effect may play a role in the hyperreactivity of vascular beds and the hypertension induced by glucocorticoids.
